Read the June Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • Time to Reassess Risks of Active Surveillance in Prostate Cancer?
  • Too Much RT Still Being Used for Bone Metastases
  • Randomized Trial of Conventional vs. Hypofractionated IMRT
  • Shared Decision Making & PSA-Based PCa Screening
  • Genomic Prostate Score (GPS) Results in the Canary AS Study
  • Doc Moyad’s No Bogus Science Column: “Intrusive Thoughts?”
  • RP Without Pelvic Lymph Node Dissection is Widely Practiced
  • Guest Column: Options for Urinary Incontinence After PCa Treatment
  • Darolutamide & ADT vs. ADT Alone in Non-Metastatic CRPC
  • Prostate SBRT Shows Positive Outcomes in Treatment of Low and Intermediate-Risk Disease

Posted in Uncategorized by with no comments yet.

Read the May Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • Defining a Role for Immunotherapy in mCRPC
  • Veteran’s Health Bill Promotes Comprehensive PCa Care Program
  • Prostatectomy of Mixed Mortality Benefit in Men with Prostate Cancer
  • Long-Term Unmet Supportive Care Needs of Prostate Cancer Survivors
  • AS vs. Immediate Treatment – Financial Incentives for Urologists
  • Doc Moyad’s No Bogus Science: “Are Low-Carb Diets Groovy Now!?”
  • Combined Biopsy Strategy Improved Prostate Cancer Diagnosis
  • 177Lu-PSMA Radionuclide Treatment in Men with Metastatic CRPC
  • PSMA PET/CT Better Detects Prostate Cancer Spread
  • Genomic Prostate Score Does Not Improve Risk Assessment
  • Its a Bust Adding Immunotherapy No Benefit in mCRPC

Posted in Uncategorized by with no comments yet.

Read the April Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • FDA Panel Thumbs Down for Cancer Focal Therapy
  • Apalutamide Benefit Sustained in Metastatic Castrate-Sensitive PCa
  • Hypofractionate RT for PCa Stands the Test of Time
  • Enzalutamide, ADT and Salvage RT in High-Risk PSA-Recurrent PCa
  • Robotic-Assisted RP & Persistent Postoperative Opioid Use
  • Doc Moyad’s No Bogus Science: “Heart Healthy = Immune Healthy = Prostate Healthy!?”
  • The Cost of Bottling Up Emotions
  • Sunitinib, Docetaxel & Prednisone in Chemo-Naïve Metastatic CRPC
  • Less Frequent Prostate Cancer Screening a Good Idea
  • Guest Column: Goodbye Poke and Hope!
  • HSD3B1 Genotype Tied to Prostate Cancer Outcomes

Posted in Uncategorized by with no comments yet.

Read the March Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • Lower Out-of-Pocket Costs for Robotic Cancer Surgery
  • More Radium-223 in mCRPC Means More Toxicity
  • Stalling ADT Use in Recurrent PCa
  • Validation of Gallium-68 PSMA PET/CT for Primary PCa Staging
  • Long-Term Follow-Up in Low-Dose-Rate Brachytherapy for PCa
  • Doc Moyad’s No Bogus Science: “Lorcaserin Bites the Dust!?”
  • Apalutamide & Overall Survival in Non-Metastatic CRPC
  • Pembrolizumab for Treating Refractory Metastatic CRPC
  • PET Spots Prostate Cancer Metastases Missed on CT, MRI
  • Modest Survival Gains Shown in Newly Diagnosed Metastatic PCa
  • Long-Term Outcomes in Gleason Grades 2 & 3 PCa with AS
  • Guest Column: Staying Sexually Active After PCa Treatment
  • Earlier Cabazitaxel Use in mCRPC

 


Posted in Uncategorized by with no comments yet.

Read the February Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • Chemo Triumphs in Second Line Metastatic Prostate Cancer
  • Salvage RT First Found Superior for Post-RP PSA Failure
  • Tailored Pelvic PT May Curb Post-RP Incontinence & Pain
  • AS, RP, EBRT or Brachytherapy With or Without ADT
  • Doc Moyad’s No Bogus Science Column: “Resistance Training!?”
  • Extended Pelvic Lymph Node Dissection & PCa Outcomes
  • More Veggies No Help in AS
  • Outcomes of Hypofractionated/ Conventionally Fractionated RT
  • Anterior-Dominant PCa Harder to Detect Than Other Locations
  • Impact of MRI & Targeted Biop-sies on Eligibility for Surveillance
  • Implications of Germline Genetic Testing in Prostate Cancer
  • Tumor-Associated Release of Prostatic Cells After Biopsies

 


Posted in Uncategorized by with no comments yet.

Read the January Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • Pembrolizumab Shows Limited Activity Against Prostate Cancer
  • When the Going Gets Tough… How to Help Yourself or a Friend
  • Olaparib in Patients with Metastatic Castrate-Resistant Prostate Cancer
  • Impact of Age at Diagnosis of De Novo Metastatic Prostate Cancer
  • Clinical Utility of a Genomic Classifier In Men Undergoing RP
  • Doc Moyad’s No Bogus Science Column: “2020—The Year of the Statin & Elvis?!”
  • Variation in the Prescription of Androgen Deprivation Therapy
  • The Role of Hypofractionated Radiotherapy for Localized PCa
  • New Tools May ID Intermediate-Risk PCa Patients Suitable for AS
  • Index of Articles Published in 2019 Us TOO Hot SHEETs

Posted in Uncategorized by with no comments yet.

Read the December Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • Scientists Identify New Family of Drugs to Combat Prostate Cancer
  • 68Ga-PSMA-11 PET Detects Residual Prostate Cancer After RP
  • Positive Phase 3 HERO Study of Oral Relugolix in Advanced PCa
  • From Canada: Night Shift Work and Risk of Prostate Cancer
  • Grade Group Prediction from RP Final Pathology on Positive MRI
  • Doc Moyad’s No Bogus Science Column: “Lifestyle Change or ISCHEMIA?”
  • Gold Nanoparticles are a Safe and Effective Treatment for PCa
  • AS for Intermediate-Risk PCa? Yes, But for Whom?
  • Oncology Patients Increasingly Ask About Diet – What to Say?
  • MRI in Early Detection of Prostate Cancer
  • Guest Column: Living w. Prostate Cancer, Talking About Sex

Posted in Uncategorized by with no comments yet.

Read the November Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • Cleveland Diagnostics’ PCa Test Gains Breakthrough Status
  • Skipping Radiotherapy After Surgery for Prostate Cancer
  • Durable Pain Control After Single RT Dose to Bone Metastases
  • “Landmark” Trial in Prostate Cancer with Mutations
  • New Blood Test is Highly Accurate and Avoids Invasive Biopsies
  • Doc Moyad’s No Bogus Science Column: “Thank you Dr. Chodak for Being You”
  • RP vs. RT for High-Risk PCa with Low PSA Levels
  • “Passing Through” – In Memory of Gerald Chodak, MD
  • Men Just Want to Have Fun in Prostate Cancer Trial

Posted in Uncategorized by with no comments yet.

Read the October Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • First Results for Nanosphere Focal Therapy in Prostate Cancer
  • Second Generation Antiandrogens Carry Heart Risks
  • Largest Real-World Study of Immunotherapy with PROVENGE
  • Phase III Study of ADT with Enzalutamide or Placebo
  • Salvage Radical Prostatectomy for Recurrent Prostate Cancer
  • Doc Moyad’s No Bogus Science: “Boring B12 Testing & Vacuuming?!”
  • Recent Global Patterns in PCa Incidence and Mortality Rates
  • Phase 1b Trial of Docetaxel, Prednisone and Pazopanib
  • Acute Toxicity from IMRT vs. Stereotactic Body RT
  • New Prostate Cancer Blood Test Could Reduce Biopsies
  • Dr. Chodak’s Bottom Line

Posted in Uncategorized by with no comments yet.

Read the September Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • FDA Approval for Darolutamide in Prostate Cancer
  • Elective Node Radiation Appears More Effective for Nodal Recurrence
  • DRE Is Still a Prognostic Tool
  • Validity of PROMIS Sexual Interest and Satisfaction Measures Post-RP
  • Toxicity of Prostate Only Versus Prostate & Pelvic Lymph Node IMRT
  • Doc Moyad’s No Bogus Science: “Boring B12 Testing & Vacuuming?!”
  • Obesity Tied to Worse Perioperative Outcomes of RP
  • Negative Predictive Value of Prostate Multi-Parametric MRI
  • Radiation Therapy May Have a Role in Oligometastatic Prostate Cancer
  • Men’s Testosterone Levels Determined by Where They Grow Up
  • Researchers Find Molecular Switch to Prolong Survival
  • Doctor Chodak’s Bottom Line

Posted in Uncategorized by with no comments yet.